Voronoi, Inc. (KOSDAQ: 310210)

Market Cap	1.76T
Revenue (ttm)	n/a
Net Income (ttm)	-36.07B
Shares Out	17.69M
EPS (ttm)	-2,171.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,416
Open	105,600
Previous Close	108,700
Day's Range	104,200 - 111,200
52-Week Range	28,350 - 125,900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 126
• Stock Exchange: KOSDAQ
• Ticker Symbol: 310210